Aim: To compare the effectiveness and safety of the glimepiridemetformin combination with the glibenclamide-metformin combination in patients with type-2 diabetes uncontrolled with metformin alone. Material and methods: This research was conducted at the department of pharmacology and followed a randomized, open-label, prospective, comparative design. 80 patients were chosen for the research based on the inclusion criteria mentioned above. The participants were randomly divided into two groups, group A and group B, with 40 participants in each group. Group A was administered a FDC of Glimepiride 1mg and Metformin 500mg orally, once day before meals, for a duration of 6 months. Group B was administered a once-daily oral dosage of FDC Glibenclamide 5mg and Metformin 500mg before meals for a duration of 6 months.